Ahmed A.E. Mourad

673 total citations
23 papers, 433 citations indexed

About

Ahmed A.E. Mourad is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Ahmed A.E. Mourad has authored 23 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Organic Chemistry and 4 papers in Oncology. Recurrent topics in Ahmed A.E. Mourad's work include Synthesis and biological activity (9 papers), Bioactive Compounds and Antitumor Agents (3 papers) and Inflammasome and immune disorders (3 papers). Ahmed A.E. Mourad is often cited by papers focused on Synthesis and biological activity (9 papers), Bioactive Compounds and Antitumor Agents (3 papers) and Inflammasome and immune disorders (3 papers). Ahmed A.E. Mourad collaborates with scholars based in Egypt, Saudi Arabia and Romania. Ahmed A.E. Mourad's co-authors include Sameh Saber, Ahmed E. Khodir, Eman El‐Ahwany, Noha A. Amin, Peter G. Jones, Ahmed Shata, Galal Yahya, Ahmed S. Saad, Eslam E. Abd El-Fattah and Simona Cavalu and has published in prestigious journals such as Life Sciences, Frontiers in Pharmacology and Biomedicine & Pharmacotherapy.

In The Last Decade

Ahmed A.E. Mourad

23 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ahmed A.E. Mourad Egypt 12 211 132 59 53 37 23 433
Zeping Zuo China 11 297 1.4× 63 0.5× 77 1.3× 35 0.7× 48 1.3× 31 542
Mengjie Xiao China 14 280 1.3× 79 0.6× 66 1.1× 27 0.5× 41 1.1× 37 588
Ahmed R. El‐Sheakh Egypt 15 149 0.7× 136 1.0× 33 0.6× 28 0.5× 20 0.5× 24 540
Teresa Rossi Italy 12 255 1.2× 122 0.9× 78 1.3× 29 0.5× 37 1.0× 28 564
Waseem El‐Huneidi United Arab Emirates 15 257 1.2× 59 0.4× 41 0.7× 64 1.2× 30 0.8× 61 653
Laura Llorach-Parés Spain 10 205 1.0× 67 0.5× 47 0.8× 28 0.5× 29 0.8× 12 412
Yue Xu China 14 305 1.4× 138 1.0× 69 1.2× 113 2.1× 33 0.9× 35 664
Sharon Campbell United States 12 242 1.1× 146 1.1× 75 1.3× 18 0.3× 35 0.9× 16 648
Ju-Ryoung Kim South Korea 7 279 1.3× 80 0.6× 32 0.5× 33 0.6× 27 0.7× 8 501
Xiaonan Cong China 7 199 0.9× 54 0.4× 47 0.8× 25 0.5× 34 0.9× 8 399

Countries citing papers authored by Ahmed A.E. Mourad

Since Specialization
Citations

This map shows the geographic impact of Ahmed A.E. Mourad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmed A.E. Mourad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmed A.E. Mourad more than expected).

Fields of papers citing papers by Ahmed A.E. Mourad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmed A.E. Mourad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmed A.E. Mourad. The network helps show where Ahmed A.E. Mourad may publish in the future.

Co-authorship network of co-authors of Ahmed A.E. Mourad

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmed A.E. Mourad. A scholar is included among the top collaborators of Ahmed A.E. Mourad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmed A.E. Mourad. Ahmed A.E. Mourad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Elmorsy, Elsayed A., Rabab S. Hamad, Mustafa Ahmed Abdel‐Reheim, et al.. (2024). Nicardipine-chitosan nanoparticles alleviate thioacetamide-induced acute liver injury by targeting NFκB/NLRP3/IL-1β signaling in rats: Unraveling new roles beyond calcium channel blocking. International Immunopharmacology. 141. 113000–113000. 6 indexed citations
3.
4.
Elmaaty, Ayman Abo, Islam Zaki, Ahmed A.E. Mourad, et al.. (2023). Novel topoisomerase II/EGFR dual inhibitors: design, synthesis and docking studies of naphtho[2′,3′:4,5]thiazolo[3,2- a ]pyrimidine hybrids as potential anticancer agents with apoptosis inducing activity. Journal of Enzyme Inhibition and Medicinal Chemistry. 38(1). 2205043–2205043. 28 indexed citations
5.
Mansour, Basem, Magda A. El‐Sherbeny, Fatmah A. M. Al-Omary, et al.. (2023). New Pyrazole-Clubbed Pyrimidine or Pyrazoline Hybrids as Anti-Methicillin-Resistant Staphylococcus aureus Agents: Design, Synthesis, In Vitro and In Vivo Evaluation, and Molecular Modeling Simulation. ACS Omega. 8(46). 44250–44264. 10 indexed citations
6.
Saber, Sameh, et al.. (2023). Salutary influence of gemifloxacin mesylate nanocubosomes based-in situ ocular gel as a novel approach for the management of experimental keratitis induced by MRSA. Journal of Drug Delivery Science and Technology. 89. 105012–105012. 6 indexed citations
7.
El-Fattah, Eslam E. Abd, Sameh Saber, Mahmoud E. Youssef, et al.. (2022). AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma. Frontiers in Pharmacology. 12. 720173–720173. 19 indexed citations
8.
Cavalu, Simona, Mahmoud E. Youssef, Ahmed A.E. Mourad, et al.. (2022). Coomassie brilliant blue G-250 dye attenuates bleomycin-induced lung fibrosis by regulating the NF-κB and NLRP3 crosstalk: A novel approach for filling an unmet medical need. Biomedicine & Pharmacotherapy. 148. 112723–112723. 32 indexed citations
9.
El-Fattah, Eslam E. Abd, Sameh Saber, Ahmed A.E. Mourad, et al.. (2022). The dynamic interplay between AMPK/NFκB signaling and NLRP3 is a new therapeutic target in inflammation: Emerging role of dapagliflozin in overcoming lipopolysaccharide-mediated lung injury. Biomedicine & Pharmacotherapy. 147. 112628–112628. 60 indexed citations
10.
Ali, Fares E.M., et al.. (2022). Fasudil Ameliorates Methotrexate-Induced Hepatotoxicity by Modulation of Redox-Sensitive Signals. Pharmaceuticals. 15(11). 1436–1436. 8 indexed citations
11.
12.
13.
14.
Mourad, Ahmed A.E., et al.. (2021). Synthesis and cytotoxicity screening of some synthesized hybrid nitrogen molecules as anticancer agents. Journal of Molecular Structure. 1242. 130722–130722. 17 indexed citations
15.
Mourad, Ahmed A.E.. (2021). POTENT UREASE INHIBITORS: DESIGN, SYNTHESIS, MOLECULAR DOCKING AND IN-SILICO ADME EVALUATION OF DIHYDROPYRIMIDINE PHTHALIMIDE HYBRIDS. ˜Al-œAzhar Journal of Pharmaceutical Sciences. 64(2). 205–223. 1 indexed citations
16.
El‐Deen, Ibrahim M., et al.. (2021). Design, Synthesis, Cytotoxic Screening and Molecular Docking Studies of Novel Hybrid Thiosemicarbazone Derivatives as Anticancer Agents. Chemistry & Biodiversity. 18(12). e2100580–e2100580. 21 indexed citations
17.
18.
Mourad, Ahmed A.E., et al.. (2020). <p>Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity</p>. Drug Design Development and Therapy. Volume 14. 3111–3130. 35 indexed citations
19.
Mourad, Ahmed A.E., et al.. (2017). Assessment of safe injection practice among nurses in Port Said General Hospital. Porto Biomedical Journal. 2(5). 232–232. 1 indexed citations
20.
Mourad, Ahmed A.E., Gehan H. Heeba, Ashraf Taye, & Mohamed A. El‐Moselhy. (2012). Comparative study between atorvastatin and losartan on high fat diet‐induced type 2 diabetes mellitus in rats. Fundamental and Clinical Pharmacology. 27(5). 489–497. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zeping Zuo Breakdown of academic impact, for papers by Mengjie Xiao Breakdown of academic impact, for papers by Ahmed R. El‐Sheakh Breakdown of academic impact, for papers by Teresa Rossi Breakdown of academic impact, for papers by Waseem El‐Huneidi Breakdown of academic impact, for papers by Laura Llorach-Parés Breakdown of academic impact, for papers by Yue Xu Breakdown of academic impact, for papers by Sharon Campbell Breakdown of academic impact, for papers by Ju-Ryoung Kim Breakdown of academic impact, for papers by Xiaonan Cong
Rankless by CCL
2026